AI Pioneer Proposes FDA-like Approval Process for AI
AI pioneer Geoffrey Hinton has proposed that AI companies should undergo a safety approval process similar to pharmaceutical regulations before releasing new products.
Geoffrey Hinton, a prominent figure in artificial intelligence research, has called for the establishment of a regulatory framework for AI that mirrors the safety approval processes used in the pharmaceutical industry.
Speaking on the "Smart Girl Dumb Questions" podcast on Tuesday, Hinton suggested that AI companies should be required to demonstrate the safety of their products to regulatory bodies before they can be released to the public. He drew a parallel to the stringent requirements faced by pharmaceutical companies when seeking approval from agencies like the U.S. Food and Drug Administration (FDA), which involves substantial investment in testing and validation.
Hinton's proposal comes amid growing concerns about the potential risks associated with advanced AI systems. Recent events, such as OpenAI reportedly delaying the release of its latest model due to safety concerns, highlight the ongoing debate within the industry regarding responsible development and deployment.
The AI researcher emphasized the accelerating pace of AI development, noting the potential for recursive self-improvement where AI systems enhance themselves. He expressed concern that without proper oversight, the rapid advancements could lead to significant challenges within a relatively short timeframe, estimating potentially serious issues could arise in one to two years.